Skip to main content
NANO MRNA Co.,Ltd. logo

NANO MRNA Co.,Ltd. — Investor Relations & Filings

Ticker · 4571 ISIN · JP3651120002 LEI · 529900L2VA2GIFZQTG17 T Professional, scientific and technical activities
Open in API
Filings indexed 70 across all filing types
Latest filing 2025-02-14 Regulatory Filings
Country JP Japan
Listing T 4571

About NANO MRNA Co.,Ltd.

https://www.nanomrna.co.jp/

NANO MRNA Co., Ltd. is a biotechnology firm that operates as a platform company and an IP Generator specializing in mRNA-based medicine. The company focuses on creating and out-licensing intellectual property for novel therapeutics by connecting drug discovery seeds with medical and development needs. It leverages a proprietary drug delivery system (DDS) based on micellar nanoparticle technology to advance its pipeline. Key clinical programs include an mRNA therapy for osteoarthritis (RUNX1 mRNA) and an antisense oligonucleotide (ASO) for glioblastoma (TUG1 ASO). Evolving from its predecessor, NanoCarrier, the company combines a legacy of R&D in nanoparticle technology with a strategic focus on RNA drug discovery. It also co-developed and markets Comlex®, an antibacterial agent for ear, nose, and throat conditions.

Recent filings

Filing Released Lang Actions
臨時報告書
Regulatory Filings Classification · 100% confidence The document is explicitly titled "臨時報告書" (Extraordinary Report or Timely Disclosure Report) and is submitted to the Kanto Local Finance Bureau Director ("関東財務局長"). The filing reason states that an event has occurred that significantly impacts the company's financial condition, operating results, and cash flow, citing Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act. The content details a specific financial event: recording an impairment loss on investment securities (投資有価証券評価損) resulting in a special loss (特別損失) for the third quarter. This type of immediate, material disclosure in Japan, which is not a standard periodic report (like 10-K or IR), falls best under the general category of Regulatory Filings (RNS) or potentially a specific type of timely disclosure not explicitly listed. Given the options, RNS (Regulatory Filings) is the most appropriate fallback for a non-standard, mandatory, timely disclosure of a significant event that impacts financials, as it is a general regulatory filing. * It is not 10-K (Annual Report) or IR (Interim Report) as it is a specific event disclosure. * It is not ER (Earnings Release) as it details a specific non-operating event (impairment). * It is not a Report Publication Announcement (RPA) because it contains the substance of the disclosure (the impairment details and amounts), not just an announcement that a report is available. * Therefore, RNS (Regulatory Filings) is the best fit for this specific, timely regulatory disclosure document.
2025-02-14 Japanese
臨時報告書
Regulatory Filings Classification · 100% confidence The document is explicitly titled "臨時報告書" (Extraordinary Report or Timely Disclosure Report) and is submitted to the Kanto Local Finance Bureau Director on November 18, 2024. Section 1 states the reason for filing is due to an event significantly impacting the financial condition, operating results, or cash flow, citing Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act and relevant Cabinet Office Ordinance provisions. The content details a specific financial event: recording an impairment loss on investment securities (特別損失に計上するものであります). This structure—a formal, timely disclosure of a significant, non-periodic financial event—aligns best with the general category for regulatory announcements that don't fit specific periodic reports (like 10-K or IR) or specific corporate actions (like DIV or CAP). Given the options, 'Regulatory Filings' (RNS) is the most appropriate general category for this type of mandatory, non-standard disclosure under Japanese financial regulations, as it is a specific form of regulatory filing that isn't covered by the other specialized codes.
2024-11-18 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document title explicitly states "第２四半期報告書" (Second Quarter Report) and references the fiscal period "第29期中（自 2024年４月１日 至 2024年９月30日）" (29th term, from April 1, 2024, to September 30, 2024). This content confirms the document is a comprehensive financial report covering a period shorter than a year. This aligns perfectly with the definition of an Interim / Quarterly Report (Code: IR). The document structure, including confirmation by the CEO and CFO regarding the appropriateness of the filing under financial instruments laws, supports this classification.
2024-11-14 Japanese
半期報告書－第29期(2024/04/01－2025/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '第２四半期報告書' (Second Quarter Report) for NANO MRNA Co., Ltd., covering the period from April 1, 2024, to September 30, 2024. It contains detailed financial statements (balance sheet, income statement, cash flow analysis) and management discussion, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2025
2024-11-14 Japanese
臨時報告書
AGM Information Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and is submitted to the Kanto Local Finance Bureau Director on July 1, 2024. Section 1 explicitly states the reason for filing is due to resolutions passed at the Annual General Meeting (AGM) held on June 27, 2024, citing Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act. Section 2 details the resolution: the election of 4 directors and the voting results (votes for, against, abstentions, and passing percentage). This content—reporting the results of a shareholder vote following a general meeting—directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it relates to the AGM, DVA is the specific code for the *results* of the vote, whereas AGM-R is for presentations/materials *shared during* the meeting.
2024-07-01 Japanese
内部統制報告書－第28期(2023/04/01－2024/03/31)
Governance Information Classification · 100% confidence The document is explicitly titled "内部統制報告書" (Internal Control Report) in the cover page and throughout the text. It references the legal basis as Article 24-4-4, Paragraph 1 of the Financial Instruments and Exchange Act (金融商品取引法第24条の４の４第１項), which mandates the filing of an Internal Control Report in Japan. The content details the framework, scope, criteria (as of March 31, 2024), and the conclusion that internal controls over financial reporting are effective. This directly corresponds to the requirements for an Audit Report/Information filing, specifically concerning internal controls, which aligns best with the 'Audit Report / Information (AR)' category, as it is a formal report on internal control effectiveness, distinct from a full Annual Report (10-K) or a simple Earnings Release (ER).
2024-06-28 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.